Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPL-301 in giant cell arteritis
NL-OMON49243Phase 2Active, not recruiting
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in giant cell arteritis (GCA) comparing Mavrilimumab + prednisone taper with Placebo + prednisone taper (2 arms). Primary endpoint: Time to flare by Week 26. Started Apr 2019; status: active, not recruiting.
02
Drugs
mavrilimumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NL-OMON49243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49243.